ARS Pharmaceuticals's top three insider shareholders as of March 23, 2026 are Capital Management, L.P. Ra (Director, 9.96Mn shares), James E Flynn (TenPercentOwner, 4.89Mn shares), Pratik Shah (Director, 4.47Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Capital Management, L.P. Ra | 0 | 9,958,073 | 27 Mar, 2024 | |
| James E Flynn | 0 | 4,887,254 | 01 Jul, 2025 | |
| Pratik Shah | 0 | 4,474,554 | 14 Nov, 2025 | |
| Richard E Lowenthal | President And Ceo | 4,327,189 | 0 | 09 Dec, 2024 |
| Sarina Tanimoto | Chief Medical Officer | 3,433,512 | 0 | 09 Dec, 2024 |
| Rajeev Dadoo | 0 | 3,009,677 | 10 Nov, 2022 | |
| Sarina Tanimoto | Chief Medical Officer | 0 | 1,247,447 | 21 Aug, 2025 |
| Richard E Lowenthal | President And Ceo | 0 | 1,196,494 | 22 Aug, 2025 |
| Laura Shawver | 210,346 | 0 | 08 Apr, 2025 | |
| Alexander A Fitzpatrick | Chief Legal Officer | 89,613 | 0 | 22 May, 2025 |
| Michael Kelly | 0 | 83,225 | 10 Nov, 2022 | |
| Jonathan Piazza | Chief Financial Officer | 69,225 | 0 | 04 May, 2022 |
| Valerie Odegard | President And Cso | 61,639 | 0 | 04 May, 2022 |
| Naomi Hunder | Chief Medical Officer | 54,427 | 0 | 04 May, 2022 |
| Russ Hawkinson | Sr. Vice President Of Finance | 37,251 | 0 | 04 May, 2022 |
| Brian Dorsey | Chief Operating Officer | 10,789 | 0 | 14 Nov, 2025 |
| Eric Karas | Chief Commercial Officer | 10,315 | 0 | 03 Jul, 2025 |
| Kathleen D. Scott | Chief Financial Officer | 10,042 | 0 | 22 Aug, 2025 |
| Kathleen D. Scott | Chief Financial Officer | 0 | 8,250 | 01 Dec, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Jan, 2026 | Richard E Lowenthal | Stock option (right to buy) | A | 875,000 | $0.00 | 875,000 | D | A |
| 02 Jan, 2026 | Kathleen D. Scott | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Alexander A Fitzpatrick | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Eric Karas | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Justin Chakma | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Sarina Tanimoto | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Brian Dorsey | Stock option (right to buy) | A | 240,000 | $0.00 | 240,000 | D | A |
| 02 Jan, 2026 | Richard E Lowenthal | Stock Option (right to buy) | A | 240,000 | $0.00 | 240,000 | I | A |
| 02 Jan, 2026 | Sarina Tanimoto | Stock Option (right to buy) | A | 875,000 | $0.00 | 875,000 | I | A |
| 12 Nov, 2025 | Justin Chakma | Common Stock | A | 30,000 | $0.84 | 166,380 | D | M |
| 13 Nov, 2025 | Brian Dorsey | Common Stock | A | 21,828 | $0.64 | 32,617 | D | M |
| 12 Nov, 2025 | Pratik Shah | Common Stock | D | 250,000 | $0.00 | 4,574,554 | I | G |
| 12 Nov, 2025 | Justin Chakma | Common Stock | D | 30,000 | $8.91 | 136,380 | D | S |
| 12 Nov, 2025 | Pratik Shah | Common Stock | D | 100,000 | $0.00 | 4,474,554 | I | G |
| 13 Nov, 2025 | Brian Dorsey | Common Stock | D | 21,828 | $8.71 | 10,789 | D | S |
| 12 Nov, 2025 | Justin Chakma | Common Stock | D | 136,380 | $8.86 | 0 | D | S |
| 13 Nov, 2025 | Brian Dorsey | Stock Option (Right to Buy) | D | 21,828 | $0.00 | 0 | D | M |
| 12 Nov, 2025 | Justin Chakma | Stock Option (Right to Buy) | D | 30,000 | $0.00 | 89,047 | D | M |
| 21 Aug, 2025 | Richard E Lowenthal | Common Stock | D | 50,000 | $14.49 | 1,196,494 | I | S |
| 21 Aug, 2025 | Kathleen D. Scott | Common Stock | A | 12,500 | $1.50 | 22,542 | D | M |